Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bullish +50

The Zacks Analyst Blog Highlights RTX, Wells Fargo, Amgen, Daily Journal and Tandy Leather

📅 Zacks.com announced its Analyst Blog highlights on May 27, 2026, featuring stocks including RTX, Wells Fargo, Amgen, Daily Journal, and Tandy Leather.

✈️ RTX Corp. shares outperformed the aerospace-defense industry over the past year with a +33.7% gain versus +3.5%.

🛡️ The company secured ample orders for defense products from the Pentagon and allies while commercial air traffic improved sales.

📦 Strong volumes in large commercial engines and Pratt Canada operations helped RTX register a $271 billion backlog as of March 31, 2026.

⚠️ U.S. government import tariffs and supply-chain challenges pose risks that could adversely impact the aerospace sector.

🏦 Wells Fargo shares gained +6.4% over the past year but lagged the financial investment banking industry's +26.3% gain.

💰 The bank's net interest income recovery remains slow despite an expected Fed rate cut in 2026, pressuring revenue growth.

📉 Mortgage banking income is weak due to ongoing volatility in mortgage rates and a lower return on equity indicating reduced efficiency.

📈 Earnings surpassed estimates in three of the trailing four quarters as the removal of the asset cap allows deposit and loan growth.

🚀 Wells Fargo plans to scale fee-based businesses while enhancing its revenue mix with strong capital and liquidity support.

💊 Amgen Inc. shares outperformed the medical-biomedical industry over the past year with a +24.8% gain versus +22.3%.

🧬 The biotech company beat first-quarter estimates for both earnings and sales driven by key medicines like Evenity, Repatha, and Uplizna.

📉 Sales of best-selling drugs Prolia and Xgeva will decline sharply in 2026 due to biosimilar launches and upcoming LOE cliffs.

🧬 Amgen has several key pipeline assets with a primary focus on the obesity candidate MariTide to offset declining revenues.

📰 Daily Journal Corp. shares gained +12.2% over the past year against the publishing industry's +24.9% gain.

💻 This microcap company is evolving into a software-driven business with Journal Technologies contributing approximately 79% of total revenue in FY26.

🌍 The company's expanding presence across 37 states and international markets reflects growing adoption of its government-focused software solutions.

💰 Daily Journal maintains a highly liquid balance sheet with positive operating cash flow and reduced margin debt.

⚠️ Legacy publishing operations face structural margin pressure from rising costs, while elevated legal expenses limit operating leverage.

Bullish Signals
  • Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year, rising +24.8% compared to the industry's +22.3% gain.
  • The company beat first-quarter estimates for both earnings and sales, demonstrating strong operational performance.
  • Key medicines including Evenity, Repatha, Uplizna, Imdelltra, Tavneos, and Tezspire are driving sales growth.
  • New biosimilar launches are contributing to top-line growth, offsetting declines from mature products.
  • Amgen has several key pipeline assets with a primary focus on the obesity candidate, MariTide, offering significant upside potential.
Risk Factors
  • Amgen faces sharp sales declines for best-selling drugs Prolia and Xgeva in 2026 due to biosimilar launches.
  • Recent pipeline setbacks and upcoming loss-of-exclusivity (LOE) cliffs pose significant concerns for Amgen's future revenue growth.
  • Price declines and increased competition are actively hurting sales of some of Amgen's key products.
  • Wells Fargo's net interest income recovery may remain slow despite the expected Fed rate cut in 2026, which is pressuring revenue growth.
  • Mortgage banking income remains weak amid ongoing volatility in mortgage rates for Wells Fargo.
  • The lower return on equity at Wells Fargo indicates less efficiency in using its shareholders' funds.
  • RTX faces risks from uncertainties created by recent U.S. government-issued import tariffs affecting the aerospace sector.
  • Supply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX's operations.
Full Analysis
Zacks Equity Research analysts released new reports on Amgen Inc. (AMGN) alongside other major stocks, highlighting the biotech giant's recent financial performance and strategic outlook. The company beat first-quarter estimates for both earnings and sales, driven by key medicines such as Evenity, Repatha, Uplizna, Imdelltra, Tavneos, and Tezspire. These newer products are successfully offsetting declining revenues from oncology biosimilars and mature drugs like Enbrel. Additionally, new biosimilar launches are contributing to top-line growth, while the company maintains a strong pipeline with a primary focus on its obesity candidate, MariTide. Despite positive momentum, Amgen faces headwinds including price declines and increased competition that are hurting sales of certain products. Specifically, sales of best-selling drugs Prolia and Xgeva are expected to decline sharply in 2026 due to biosimilar launches. The analysts also note concerns regarding recent pipeline setbacks and the upcoming loss-of-exclusivity (LOE) cliff for existing revenue streams. Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year, rising 24.8% compared to the industry's 22.3% gain.